ArticleBreast cancer research and treatment2023
Contrast enhanced mammography in breast cancer surveillance.
Article in Breast cancer research and treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Fewer breast cancers during post-treatment surveillance among patients initially staged using contrast-based imaging.Breast cancer research and treatment · 2026Article
- Clinical Applications and Decision-Making Impact of Contrast-Enhanced Mammography and MRI: A Recent Structured Review.Diagnostics (Basel, Switzerland) · 2026Review
- ESR Essentials: post-treatment breast cancer surveillance from mammography to a more personalised approach-practice recommendations by the European Society of Breast Imaging.European radiology · 2026Review
- The Canadian Breast Cancer Symposium 2025: Meeting Report.Current oncology (Toronto, Ont.) · 2025Article
- Contrast-Enhanced Mammography in Breast Cancer Follow-Up: Diagnostic Value in Suspected Recurrence.Journal of imaging · 2025Article
- 조영증강 유방촬영술: 현재의 임상적 활용과 미래 방향에 대한 종합적 고찰.Journal of the Korean Society of Radiology · 2025Review
- ASBrS Keynote Address: Reimagining Stage 1 Breast Cancer-Evolution of Breast Cancer Management over the Last 120 Years.Annals of surgical oncology · 2025Article
- Breast MRI to Screen Women With Extremely Dense Breasts.Journal of magnetic resonance imaging : JMRI · 2025Review
- Contrast-enhanced mammography for breast cancer detection and diagnosis with high concentration iodinated contrast medium.Insights into imaging · 2025Article
- Preliminary Evaluation of Radiomics in Contrast-Enhanced Mammography for Prognostic Prediction of Breast Cancer.Cancers · 2025Article
- Evaluation of contrast-enhanced mammography (CEM) in the preoperative staging of breast cancer: large-scale single center experience, update to 1005 cases.La Radiologia medica · 2025Article
- Imaging in Interventional Radiology: Breast Cryoablation.Seminars in interventional radiology · 2025Review
- Contrast-enhanced mammography improves patient access to functional breast imaging.Journal of medical imaging and radiation oncology · 2025Review
- Contrast-enhanced mammography for surveillance in women with a personal history of breast cancer.Breast cancer research and treatment · 2024Article
- MR-contrast enhanced mammography (CEM) for follow-up of breast cancer patients: a "pros and cons" debate.European radiology · 2024Article
- False negative breast cancers on imaging and associated risk factors: a single institution six-year analysis.Breast cancer research and treatment · 2024Article
- Article
- State-of-the-art for contrast-enhanced mammography.The British journal of radiology · 2024Review
- Contrast-enhanced mammography BI-RADS: a case-based approach to radiology reporting.Insights into imaging · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMammography (MG) is the standard imaging in surveillance of women with a personal history of breast cancer or DCIS (PHBC), supplemented with ultrasound. Contrast Enhanced Mammography (CEM) has higher sensitivity than MG and US. We report the performance of CEM compared with MG ± US.
methodsA retrospective study of patients undergoing their first surveillance CEM in an Australian hospital setting between June 2006 and October 2020. Cases where a patient was recalled for assessment were identified, recording radiology, pathology and treatment details. Blinded re-reading of recalled cases was performed to determine the contribution of contrast. Use of surveillance US across the board was assessed for the period.
results73/1191 (6.1%) patients were recalled. 35 (48%) were true positives (TP), with 26 invasive cancers and 9 cases of DCIS, while 38 (52%) were false positive (FP) with a positive predictive value (PPV) 47.9%. 32/73 were recalled due to MG findings, while 41/73 were only recalled due to Contrast. 14/73 had 'minimal signs' with a lesion identifiable on MG with knowledge of the contrast finding, while 27/73 were visible only with contrast. 41% (17/41) recalled due to contrast were TP. Contrast-only TPs were found with low and high mammographic density (MD). Screening breast US reduced by 55% in the year after CEM was implemented.
conclusionCompared to MG, CEM as a single surveillance modality for those with PHBC has higher sensitivity and comparable specificity, identifying additional malignant lesions that are clinically significant. Investigation of interval cancer and subsequent round outcomes is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.